Ionis Pharmaceuticals Inc (IONS) Implied Volatility Current

Tracking IONS implied volatility helps you identify when options premiums on Ionis Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Ionis Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when IONS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Ionis Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For IONS, tracking metrics like IONS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on IONS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1.

In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where IONS implied volatility sits today versus where it has been. Our scanner ranks Ionis Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in IONS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Ionis Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.